CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA.
CervoMed Inc. (CRVO) ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung innovativer Therapien für neurodegenerative Erkrankungen konzentriert. Im Fokus...
